4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-22-059060
Chief Executive Officer sold 25,000 shares at an average $54.03 ($1,350,827)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2022-11-28 | Option exercise | +25,000 | $19.12 | $478,000 | 315,279 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-11-28 | Sale | −17,118 | $53.58 | $917,246 | 298,161 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-11-28 | Sale | −5,572 | $54.85 | $305,598 | 292,589 | D |
| Kulkarni Samarth Chief Executive Officer | 2022-11-28 | Sale | −2,310 | $55.40 | $127,983 | 290,279 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2022-11-28 | Option exercise · Stock Option (Right to Buy) | −25,000 | 229,582 | D | ||
| Open-market sales · 25,000 sh · avg $54.03 · $1,350,827 | |||||||
Loading xslF345X03/doc4.xml…